NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were issued to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its board has approved a stock repurchase program on Tuesday, September 19th 2017, which permits the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's management believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, May, 8th. The company reported $0.95 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.03. The company earned $3.22 billion during the quarter, compared to analysts' expectations of $3.18 billion. Henry Schein had a net margin of 3.18% and a return on equity of 19.68%. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.88 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share (EPS) guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus estimate of $4.09.

19 Wall Street analysts have issued 12-month target prices for Henry Schein's shares. Their predictions range from $73.00 to $102.00. On average, they anticipate Henry Schein's share price to reach $81.50 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price. View Analyst Ratings for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Henry Schein include Illumina (ILMN), Vertex Pharmaceuticals (VRTX), FRESENIUS SE &/S (FSNUY), Humana (HUM), Express Scripts (ESRX), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), Edwards Lifesciences (EW), ASTELLAS PHARMA/ADR (ALPMY), ESSILOR Intl S/S (ESLOY) and Fresenius Medical Care AG & Co. (FMS).

News headlines about HSIC stock have trended somewhat positive recently, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Henry Schein earned a news sentiment score of 0.19 on Accern's scale. They also assigned media coverage about the company an impact score of 45.16 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Henry Schein's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Swedbank (1.33%), Fenimore Asset Management Inc. (0.36%), Davis R M Inc. (0.30%), Riverbridge Partners LLC (0.27%), Bank of Montreal Can (0.24%) and Port Capital LLC (0.14%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Swedbank, Bank of Montreal Can, Hartford Investment Management Co., Neville Rodie & Shaw Inc., Riverbridge Partners LLC, Gateway Investment Advisers LLC and Carderock Capital Management Inc.. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was purchased by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Xact Kapitalforvaltning AB, AMG National Trust Bank, Port Capital LLC, Addenda Capital Inc., State of Alaska Department of Revenue, Trust Co. of Oklahoma and DnB Asset Management AS. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $75.31.

Henry Schein has a market capitalization of $11.60 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]